D. E. Shaw & Co., Inc. Axsome Therapeutics, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$78.93 - $95.84 $402,543 - $488,784	5,100 Added 50.0%	15,300 $1.37 Million
Q1 2024 May 15, 2024	SELL	$69.39 - $97.64 $1.69 Million - $2.38 Million	-24,400 Reduced 70.52%	10,200 $813,000
Q2 2023 Aug 14, 2023	BUY	$58.41 - $90.35 $233,640 - $361,400	4,000 Added 13.07%	34,600 $2.49 Million
Q1 2023 May 15, 2023	BUY	$58.39 - $75.0 $1.2 Million - $1.55 Million	20,600 Added 206.0%	30,600 $1.89 Million
Q4 2022 Feb 14, 2023	BUY	$39.94 - $79.72 $399,400 - $797,200	10,000 New	10,000 $771,000
Q4 2021 Feb 14, 2022	BUY	$30.7 - $43.36 $1.84 Million - $2.6 Million	60,000 Added 200.0%	90,000 $3.4 Million
Q2 2020 Aug 14, 2020	SELL	$49.87 - $98.69 $498,700 - $986,900	-10,000 Reduced 25.0%	30,000 $2.47 Million
Q1 2020 May 15, 2020	BUY	$41.2 - $101.31 $1.24 Million - $3.04 Million	30,000 Added 300.0%	40,000 $2.35 Million
Q4 2019 Feb 14, 2020	BUY	$16.71 - $106.24 $167,100 - $1.06 Million	10,000 New	10,000 $1.03 Million

325

37.7M

912K

855K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.89B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.